Abstract

BackgroundThe 10-valent pneumococcal conjugate vaccine (PCV10) was introduced in Kenya in 2011. Introduction of any PCV will perturb the existing pneumococcal population structure, thus the aim was to genotype pneumococci collected in Kilifi before PCV10. Methods and FindingsUsing multilocus sequence typing (MLST), we genotyped >1100 invasive and carriage pneumococci from children, the largest collection genotyped from a single resource-poor country and reported to date. Serotype 1 was the most common serotype causing invasive disease and was rarely detected in carriage; all serotype 1 isolates were members of clonal complex (CC) 217. There were temporal fluctuations in the major circulating sequence types (STs); and although 1-3 major serotype 1, 14 or 23F STs co-circulated annually, the two major serotype 5 STs mainly circulated independently. Major STs/CCs also included isolates of serotypes 3, 12F, 18C and 19A and each shared ≤2 MLST alleles with STs that circulate widely elsewhere. Major CCs associated with non-PCV10 serotypes were predominantly represented by carriage isolates, although serotype 19A and 12F CCs were largely invasive and a serotype 10A CC was equally represented by invasive and carriage isolates. ConclusionsUnderstanding the pre-PCV10 population genetic structure in Kilifi will allow for the detection of changes in prevalence of the circulating genotypes and evidence for capsular switching post-vaccine implementation.

Highlights

  • Introduction of anypneumococcal conjugate vaccine (PCV) will perturb the existing pneumococcal population structure, the aim was to genotype pneumococci collected in Kilifi before PCV10

  • Understanding the pre-PCV10 population genetic structure in Kilifi will allow for the detection of changes in prevalence of the circulating genotypes and evidence for capsular switching post-vaccine implementation

  • Children in resource-poor countries have a much higher incidence of life-threatening pneumococcal disease [3,4], the World Health Organisation recommended that PCV be introduced into developing countries with high childhood mortality, and the GAVI Alliance has provided support for PCV introduction [5]

Read more

Summary

Introduction

Introduction of anyPCV will perturb the existing pneumococcal population structure, the aim was to genotype pneumococci collected in Kilifi before PCV10. Children in resource-poor countries have a much higher incidence of life-threatening pneumococcal disease [3,4], the World Health Organisation recommended that PCV be introduced into developing countries with high childhood mortality, and the GAVI Alliance has provided support for PCV introduction [5]. Pneumococcal disease burden among young children living within the Kilifi collected though routine surveillance at Kilifi District Hospital. They approved the analysis of carriage isolates collected in specific research studies; for these studies individual informed consent was obtained from every parent/guardian. The 10-valent pneumococcal conjugate vaccine (PCV10) was introduced in Kenya in 2011

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call